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A fundamental challenge in cancer genomics is to
design effective, personalized treatments based on the
mutational profiles of tumors. Pharmacological targeting
of the numerous aberrant pathways found in individual
tumors remains exceedingly challenging, but T cell-
based therapies are an attractive alternative because of
the enormous diversity and exquisite specificity of anti-
gen recognition. We assessed the immunogenicity of
three common driver mutations in human lymphoma –
MYD88L265P, EZH2Y641N, and EZH2Y641F – to evaluate
their suitability as targets for immunotherapy. Antigen
presenting cells were loaded with overlapping peptide
libraries containing each mutation and used to stimulate
autologous T cells from healthy donors and lymphoma
patients. Stimulated T cells were screened by interferon-
gamma ELISPOT for reactivity to mutant versus wild-
type peptides as well as full-length proteins. All three
peptide libraries elicited T cell responses from multiple
donors representing diverse HLA haplotypes. Moreover,
we identified peptides from MYD88L265P and EZH2Y641N
that were naturally processed and presented, and the
corresponding T cell responses were specific for mutant
proteins. Thus, MYD88L265P and EZH2Y641N both repre-
sent compelling antigens for immunotherapy of lym-
phoma patients. Funding was provided by the BC Cancer
Foundation, the Canadian Cancer Society, and the Wal-
denstrom’s Macroglobulinemia Foundation of Canada.
Authors’ details
1BC Cancer Agency, Victoria, BC, Canada. 2Simon Fraser University, Burnaby,
BC, Canada. 3BC Cancer Agency, Vancouver, BC, Canada. 4Dana-Farber
Cancer Institute, Boston, MA, USA. 5University of British Columbia, Vancouver,
BC, Canada.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P386
Cite this article as: Nielsen et al.: Immunogenicity of recurrent
mutations in MYD88 and EZH2 in non-Hodgkin lymphomas. Journal for
Immunotherapy of Cancer 2015 3(Suppl 2):P386.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit1BC Cancer Agency, Victoria, BC, Canada
Full list of author information is available at the end of the article
Nielsen et al. Journal for Immunotherapy of Cancer 2015, 3(Suppl 2):P386
http://www.immunotherapyofcancer.org/content/3/S2/P386
© 2015 Nielsen et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
